The cost-utility analysis by Hughes et al demonstrated that using adalimumab for treating uveitis in the UK is not cost-effective compared with methotrexate alone. 

     We wish to address 2 issues: (1) the Health Utilities Index (HUI) III

sensitivity for quantifying ophthalmic quality of life (QOL) and (2)

the discriminatory aspects of multiattribute QOL instruments (the

HUI III and EuroQOL-5D).